Microbiome-Based Therapeutic Innovations for Improving Gynecological and Obstetric Health
DOI:
https://doi.org/10.64784/250Palabras clave:
vaginal microbiome, vaginal dysbiosis, probiotics, prebiotics, postbiotics, live biotherapeutic products, vaginal microbiota transplantation, bacterial vaginosis, gynecological diseases, obstetric complications, reproductive health, precision medicineResumen
The vaginal microbiome has emerged as a fundamental determinant of female reproductive health and a promising therapeutic target for the prevention and management of gynecological and obstetric complications. This review aimed to critically analyze the current scientific evidence regarding emerging microbiome-targeted therapeutic approaches, emphasizing their biological mechanisms, clinical effectiveness, therapeutic potential, and future applications in personalized reproductive medicine. A structured narrative review based on the Scientific Method was conducted using publications retrieved from internationally recognized databases, including PubMed, Scopus, Web of Science, ScienceDirect, SpringerLink, Nature Portfolio, and Google Scholar. Recent evidence demonstrates that vaginal dysbiosis is strongly associated with bacterial vaginosis, recurrent vulvovaginal candidiasis, infertility, recurrent urinary tract infections, preterm birth, and other adverse pregnancy outcomes. The analyzed literature indicates that probiotics currently possess the strongest clinical evidence, while live biotherapeutic products, vaginal microbiota transplantation, postbiotics, prebiotics, and advanced vaginal drug delivery systems represent rapidly evolving therapeutic alternatives with considerable potential for restoring microbial homeostasis. These interventions extend beyond pathogen elimination by promoting immune regulation, epithelial barrier integrity, long-term microbial stability, and personalized therapeutic strategies. Although important methodological limitations remain, including heterogeneity among studies and limited long-term clinical data, microbiome-directed therapies are expected to play an increasingly significant role in precision reproductive medicine. Continued multidisciplinary research and high-quality clinical trials will be essential to facilitate their safe and effective integration into routine gynecological and obstetric practice.
Referencias
• Bassey, P.-O. O., Ilomuanya, M. O., Oseni, B. A., Ogundemuren, D. A., Oyediran, K. O., & Ekeji, E. N. (2025). Advancements in drug delivery systems for women’s reproductive health: Vaginal microbiome as a target for innovative drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 215, 114831. https://doi.org/10.1016/j.ejpb.2025.114831
• Dillen, J., et al. (2026). The female urogenital microbiome: Ecological insights, therapeutic strategies, and molecular mechanisms. Cell Host & Microbe, 34(4), 567–587. https://doi.org/10.1016/j.chom.2026.03.015
• Cheong, K.-L., Pan, T., Wang, M., Wang, D., & Zhong, S. (2026). Impact of prebiotics, probiotics, and postbiotics on maternal and fetal health: Mechanisms, efficacy, and safety across pregnancy. Pediatric Research. https://doi.org/10.1038/s41390-026-04983-9
• Sahu, B. K., Panda, S. K., Mallick, U., Panda, S. H., & Sahu, M. C. (2026). The role of probiotics in restoring and maintaining vaginal microbiome health: A review. Infection and Immunity. https://doi.org/10.1128/iai.00011-26
• Li, Y., et al. (2026). Targeting vaginal dysbiosis: Prospects for the application of live biotherapeutics products. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1749581
• van de Wijgert, J. H. H. M., & Verwijs, M. C. (2020). The vaginal microbiome: What have we learned after a decade of molecular characterization? PLoS ONE, 15(8), e0237064.
• Petrova, M. I., Reid, G., Vaneechoutte, M., & Lebeer, S. (2017). Lactobacillus iners: Friend or foe? Trends in Microbiology, 25(3), 182–191.
• France, M. T., Ma, B., Gajer, P., Brown, S., & Brotman, R. M. (2022). VALENCIA: A nearest centroid classification method for vaginal microbial communities. Microbiome, 10, 1–15.
• Ma, B., France, M. T., Crabtree, J., et al. (2020). A comprehensive non-redundant gene catalog reveals extensive within-community intraspecies diversity in the human vagina. Nature Communications, 11, 940.
• Fettweis, J. M., Serrano, M. G., Brooks, J. P., et al. (2019). The vaginal microbiome and preterm birth. Nature Medicine, 25, 1012–1021.
• Callahan, B. J., DiGiulio, D. B., Goltsman, D. S. A., et al. (2017). Replication and refinement of a vaginal microbial signature of preterm birth. mSystems, 2(2), e00381-16.
• Kroon, S. J., Ravel, J., & Huston, W. M. (2018). Cervicovaginal microbiota, women’s health, and reproductive outcomes. Fertility and Sterility, 110(3), 327–336.
• Ravel, J., Gajer, P., Abdo, Z., et al. (2011). Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences, 108(Suppl. 1), 4680–4687.
• O’Hanlon, D. E., Moench, T. R., & Cone, R. A. (2013). Vaginal pH and microbicidal lactic acid when Lactobacilli dominate the microbiota. PLoS ONE, 8(11), e80074.
• Reid, G. (2018). Probiotics for urogenital health. Nutrients, 10(12), 1912.
• Mendling, W., et al. (2022). An update on the role of vaginal microbiota in bacterial vaginosis, vulvovaginal candidiasis and recurrent urinary tract infections. Archives of Gynecology and Obstetrics, 305, 1147–1160.
• Green, K. A., Zarek, S. M., Catherino, W. H. (2015). Gynecologic health and the microbiome. Obstetrics and Gynecology Clinics of North America, 42(4), 701–716.
• Muzny, C. A., & Schwebke, J. R. (2022). Pathogenesis of bacterial vaginosis: Discussion of current hypotheses. Journal of Infectious Diseases, 226(Suppl. 2), S110–S116.
• Kalia, N., Singh, J., & Kaur, M. (2020). Microbiota in vaginal health and pathogenesis of recurrent infections. Archives of Microbiology, 202, 1983–1994.
• Martin, D. H. (2022). The microbiota of the vagina and its influence on women’s health and disease. American Journal of the Medical Sciences, 364(2), 103–112.
